Endocarditis, Prosthetic Valve & Device Infection (FDG-PET)

Quick Answer

FDG-PET/CT images activated leukocyte glucose uptake at infected cardiac hardware, and is now embedded in the ESC modified diagnostic criteria for prosthetic-valve endocarditis (PVE): abnormal FDG uptake around a prosthetic valve (>3 months post-implant) counts as a major criterion. It also localizes cardiac-implantable-electronic-device (CIED) pocket and lead infection and vascular-graft infection. The study only works with myocardial glucose suppression (high-fat/very-low-carb diet, fasting, ± heparin — the same prep as cardiac sarcoid). Its biggest limitation is native-valve endocarditis (lower sensitivity) and early post-surgical inflammation (<3 months), which mimics infection.

Background & Clinical Importance

Infective endocarditis is hard to diagnose when echocardiography is equivocal — especially with prostheses and devices, where shadowing and artifact limit echo and vegetations may be small. Molecular imaging adds a whole-body map that finds the valve/device focus and distant septic emboli or a portal of entry. PVE and CIED infection carry high mortality, and early, confident localization changes management (device extraction, surgery, targeted antibiotics).

Pathophysiology / Mechanism

Infected tissue recruits neutrophils and macrophages with high glycolytic demand, which trap FDG — so uptake marks active infection/inflammation, not the organism. Because normal myocardium avidly uses glucose, unsuppressed hearts show intense diffuse uptake that masks peri-valvular or lead infection; dietary suppression shifts myocardial metabolism to free fatty acids so only inflammatory foci light up.

Clinical Indications

• Prosthetic-valve endocarditis — suspected PVE with negative/equivocal echo (ESC major criterion when uptake is abnormal, >3 months post-op).
• CIED infection — differentiating pocket-only infection from lead/systemic involvement (which mandates complete extraction).
• Vascular-graft / endograft infection and LVAD infection.
• Embolic/source survey — whole-body FDG finds septic emboli, spondylodiscitis, and occult primary foci that satisfy additional criteria.

Preparation & Protocol (the make-or-break step)

• Myocardial suppression: high-fat, very-low/no-carbohydrate meals for ~24 h, then a prolonged fast (≥12 h), ± unfractionated heparin before injection — identical logic to cardiac-sarcoid prep.
• Standard cardiac-gated or ungated PET/CT; contrast CT/CTA correlation improves anatomic localization; delayed imaging can improve target-to-background.
• Document suppression adequacy before reading.

Interpretation & Decision

• PVE: focal or heterogeneous uptake around the sewing ring/peri-valvular region = suspicious; homogeneous, diffuse ring uptake is less specific and can be post-surgical.
• CIED: uptake at the pocket (± superficial) suggests localized infection; uptake along the lead / intracardiac portion or valve signals systemic infection requiring complete system extraction.
• Timing caveat: <3 months post-implant, physiologic post-surgical inflammation and surgical adhesives (BioGlue) cause uptake — interpret cautiously; the ESC major-criterion threshold is >3 months.
• Complementary WBC SPECT/CT (labeled leukocytes) is more specific and helps when FDG is equivocal or the post-op window is short.

Differential Diagnosis / Confounders

Post-surgical inflammation (<3 months), surgical adhesives/felt, active thrombus/foreign-body reaction, non-infective inflammation (vasculitis, sarcoid), and physiologic myocardial uptake from failed suppression.

Reporting Checklist

• Confirm suppression adequacy; state prep.
• Localize uptake: peri-valvular / pocket / lead / graft, and pattern (focal-heterogeneous vs diffuse).
• Note time since surgery (the <3-month caveat).
• Report extracardiac foci (emboli, spondylodiscitis, portal of entry).
• State whether findings meet an ESC major criterion.

Common Pitfalls

• Failed myocardial suppression → diffuse uptake masking or mimicking infection (commonest cause of a non-diagnostic study).
• Early post-surgical (<3 months) inflammation and surgical adhesives over-called as PVE.
• Reading CIED pocket uptake without assessing the lead (systemic vs local changes management).
• Lower sensitivity for native-valve endocarditis (small vegetations).

Board Pearls

FDG-PET/CT images activated-leukocyte glucose uptake at infected hardware and is an ESC major criterion for prosthetic-valve endocarditis — abnormal peri-valvular uptake >3 months post-op. It also maps CIED pocket vs lead/systemic infection (lead involvement mandates complete extraction) and vascular-graft infection, plus whole-body septic emboli. The study requires myocardial glucose suppression (high-fat/very-low-carb, fast, ± heparin) — the same prep as cardiac sarcoid.

The dominant pitfalls are failed suppression (diffuse myocardial uptake masking/mimicking infection — the commonest non-diagnostic cause) and early post-surgical inflammation (<3 months) and surgical adhesives, which mimic PVE. Focal/heterogeneous peri-valvular uptake is suspicious; diffuse homogeneous ring uptake is less specific.

Native-valve endocarditis has lower FDG sensitivity (small vegetations). Labeled-WBC SPECT/CT is more specific and complements FDG, especially in the early post-op window. For CIED, distinguishing pocket-only from lead/valve involvement is the management-defining call (local debridement vs full extraction).

Related Pages

• Tracer: FDG; contrast: labeled-leukocyte scintigraphy (more specific), cardiac sarcoidosis (identical suppression prep); overview: infection & inflammation imaging.

Figure / Diagram Suggestions

• A peri-valvular focal vs diffuse uptake teaching pair (PVE vs post-op).
• A CIED pocket vs lead infection schematic (local vs systemic → extraction).
• A suppression-prep timeline shared with cardiac sarcoid.

Self-Check